NCT01796717 - Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions

Nosocomial Pneumonia

Interventions

DRUG

C Group

Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes

DRUG

E Group

Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours

Trial Locations (2)

RECRUITING

TianjinCIH, Tianjin

RECRUITING

TianjinCIH, Tianjin